Type A - Science Applications International Corporation (SAIC) 20260914 Stock Analysis

📅 Science Applications International Key Upcoming Events

• October 09, 2026 Ex-Dividend Record Date for Quarterly Dividend (Confirmed)
  • Description: SAIC shareholders of record will become eligible for the $0.37 quarterly dividend payable on October 23, 2026, continuing the company’s combined dividend-and-repurchase capital-return program.
• December 03, 2026 Q3 Fiscal 2027 Earnings Release (Estimated)
  • Description: Based on SAIC’s established quarterly reporting cadence, the next results should provide the first major test of whether the Q2 rebound in organic growth can persist and whether the company can deliver its raised FY2027 revenue, margin, EPS and free-cash-flow outlook.

🏢 Step 1: Science Applications International Company Overview & Business Model

Q1-A1. What is Science Applications International?

• Company Name (Ticker): Science Applications International Corporation (SAIC)
• Sector: Technology
• Exchange: NASDAQ
• Founded: September 27, 2013
• Listing Date: September 30, 2013
• Fiscal Year End: January (52/53-week)
• Headquarters: United States, Reston
• CEO: James Reagan
• Market Cap: $5.44B
• Shares Outstanding: 41.90M
• Current Stock Price: $129.90
• Annual Dividend Yield: 1.14%
• Ex-dividend Date: October 09, 2026 (ET)
• As-of: September 14, 2026 (ET)

Q1-A2. How Does Science Applications International Make Money?

• Mission-Critical Government Technology Integration: SAIC earns revenue by providing engineering, digital modernization, mission IT, cloud, cyber, artificial-intelligence integration, training, simulation and systems-engineering services primarily to U.S. federal agencies. The business monetizes long-duration government contracts and task orders rather than proprietary mass-market software, with customers paying SAIC to integrate technology, people and domain expertise into mission-critical systems.
• Contract-Based Revenue Engine: Approximately 61% of recent revenue came from cost-reimbursement contracts, roughly 23% from time-and-materials arrangements and approximately 16% from fixed-price contracts, creating relatively durable revenue visibility while limiting the pure software-style margin scalability available to product companies.
• Government Relationship Advantage: SAIC operates roughly 1,700 active contracts and task orders and employs approximately 23,000 people. Its economic value is built around security-cleared talent, past performance, embedded customer knowledge and the ability to act as a prime contractor on complex government modernization programs.

Q1-A3. Science Applications International’s Revenue Segments & Core Income Sources

• Defense & Intelligence Is the Core Franchise: Q2 FY2027 Defense & Intelligence revenue was approximately $1.45B, representing about 77.1% of quarterly revenue, versus roughly $1.37B a year earlier. This segment covers defense, intelligence, space, mission engineering, digital modernization and related national-security programs.
• Civilian Provides Diversification: Q2 FY2027 Civilian revenue was approximately $431M, or 22.9% of quarterly revenue, versus about $395M a year earlier. The segment serves federal civilian agencies with enterprise IT, digital modernization and mission-support work.
• FY2026 Segment Mix: Defense & Intelligence revenue was approximately $5.58B, or 76.9%, while Civilian contributed approximately $1.68B, or 23.1%, confirming that SAIC remains overwhelmingly a national-security-oriented technology integrator.
• Customer Concentration: Federal customers account for virtually all revenue, with defense-related customers representing more than half of recent sales and intelligence and other federal agencies accounting for most of the balance. Commercial, state and local exposure remains immaterial.
• Growth Driver: The most attractive incremental growth is coming from higher-end digital engineering, cyber, intelligence, space, AI-enabled mission solutions and large modernization recompetes rather than from expansion of lower-value commodity IT outsourcing.

Q1-A4. Who Are Science Applications International’s Competitors?

• Direct Competitors: SAIC competes principally with Leidos, Booz Allen Hamilton, CACI International, KBR, Parsons and the government-IT operations of larger defense contractors such as General Dynamics. Competition centers on past performance, technical capability, security clearances, price, contract vehicles and access to specialized employees.
• Substitutes: U.S. government agencies can perform functions internally, procure technology directly from large cloud and software vendors, or shift work toward smaller specialist contractors. These alternatives cap SAIC’s pricing power even when customer switching costs are meaningful.
• Industry Position: SAIC is one of the largest pure-play U.S. government technology integrators, with approximately $7.4B of TTM revenue and more than $22B of backlog. It lacks the proprietary-platform economics of a software vendor, but its installed contract base, cleared workforce and customer relationships give it scale advantages over smaller competitors.
• Competitive Differentiation: SAIC’s strongest relative positioning is in technically demanding mission integration where government customers need a contractor capable of combining engineering, software, cloud, data, AI, cyber and operational expertise under one accountable prime contractor.

Q1-A5. Science Applications International Key Events: Past 12 Months

• October 06, 2025 Announced the $205M acquisition of SilverEdge Government Solutions
  • Description: SAIC agreed to acquire SilverEdge to deepen its cyber, software, AI and data-analytics capabilities in intelligence and defense markets, deliberately shifting portfolio mix toward higher-value mission technology.
• October 15, 2025 Completed the SilverEdge acquisition
  • Description: SAIC completed the transaction for approximately $203M net of acquired cash, funded with borrowings and cash. The acquisition added specialized intelligence-community capabilities but also increased integration requirements and leverage.
• October 23, 2025 James Reagan appointed interim Chief Executive Officer
  • Description: The board replaced Toni Townes-Whitley with veteran government-services executive James Reagan while reaffirming financial guidance, marking a major leadership reset after a period of weak organic growth.
• February 17, 2026 James Reagan appointed permanent Chief Executive Officer
  • Description: The board unanimously made Reagan permanent CEO, signaling confidence in his operational plan centered on consistent growth, execution discipline and stronger shareholder value creation.
• June 09, 2026 Won an approximately $192M U.S. Air Force Advanced Battle Management System contract
  • Description: The award strengthened SAIC’s position in next-generation command-and-control and digital battle-management programs, areas with strategically attractive long-term defense spending.
• July 30, 2026 Received an approximately $70M radar modernization task order
  • Description: The award demonstrated continuing demand for SAIC’s mission-engineering capabilities and added support to the company’s defense modernization pipeline.
• August 05, 2026 Secured an approximately $400M intelligence-community recompete
  • Description: The award protected a meaningful existing revenue stream and reinforced SAIC’s incumbency advantage in classified mission work, although successful recompetes primarily defend rather than automatically expand organic revenue.
• August 31, 2026 Q2 Fiscal 2027 Earnings Release
  • Description: Revenue increased 6.3% to $1.88B, organic revenue grew 5.3%, adjusted EBITDA reached $193M with a 10.3% margin, adjusted EPS was $3.01, and FCF was $131M. Management raised FY2027 revenue, EBITDA, margin and EPS guidance, although trailing-twelve-month book-to-bill remained only 0.8x.

Q1-A6. Step 1 Key Takeaways

• Step 1 Summary: SAIC is a scaled, cash-generative U.S. government technology integrator whose moat comes from contract incumbency, cleared talent and mission expertise rather than proprietary software economics. Recent leadership changes, SilverEdge integration and renewed contract momentum are improving the story, but sustainable organic growth remains the central unresolved issue.

🏰 Step 2: Science Applications International’s Economic Moat, Growth & Capital Allocation

Q2-A1. Does Science Applications International Have a Durable Economic Moat?

• Entry Barriers: Security clearances, classified-facility access, long procurement cycles, government-specific certifications, past-performance records and intimate knowledge of mission systems make entry difficult for ordinary technology-service competitors.
• Switching Costs: Mission-critical programs are costly and risky to transition because a replacement contractor must replicate personnel clearances, systems knowledge, customer relationships and operational continuity. These costs materially improve incumbent recompete odds.
• Intangible Assets: SAIC’s brand with U.S. federal agencies, contract-vehicle access, decades of past performance and approximately 1,700 active contracts and task orders represent valuable intangible assets even though they do not create monopoly economics.
• Pricing Power: Pricing power is moderate rather than exceptional. Government customers are sophisticated buyers and many contracts are competed on price, while cost-reimbursement structures can pass through certain expenses but constrain extraordinary margins.
• Profitability Defense: Current ROIC of approximately 12.4% exceeds an estimated WACC around 5.3%, producing a positive spread of roughly 7.1 percentage points. This demonstrates real economic value creation, although not the extreme returns characteristic of asset-light proprietary software.

Q2-A2. Is Science Applications International’s Growth Sustainable?

• Industry Structure and Outlook: U.S. defense, intelligence, space, cyber and federal digital-modernization spending represents a very large, durable addressable market supported by national-security priorities, aging government IT infrastructure and growing demand for AI-enabled mission systems. The market is structurally attractive but highly competitive and procurement-driven.
• Growth Sustainability: SAIC has structural exposure to favorable modernization themes, but its own growth has been uneven: FY2026 revenue declined 2.9%, FY2027 organic revenue guidance remains -2% to 0%, and trailing-twelve-month book-to-bill is only 0.8x despite a strong Q2.
• Downside Scenarios:
  • 1 Recompete Losses Outpace New Awards: Major incumbent contracts roll off faster than replacement wins ramp, causing backlog conversion and organic revenue to remain negative even if headline award announcements appear strong.
  • 2 Federal Procurement Delays Intensify: Continuing resolutions, shutdown risk, delayed appropriations or changing agency priorities postpone task orders and contract starts, pushing revenue and cash generation to later periods.
  • 3 Higher-Growth Competitors Win Share: CACI, Booz Allen, Leidos and specialist cyber or space firms win more high-value programs, leaving SAIC concentrated in slower-growing legacy work and limiting its ability to rerate.

Q2-A3. How Does Science Applications International Allocate Capital & Return Cash?

• Share Repurchases: SAIC reduced shares outstanding by approximately 7.76% YoY, and TTM repurchases were roughly $479M. This is a powerful per-share compounding mechanism at current valuation levels.
• Dividend: The annual dividend is $1.48 per share, producing a yield of approximately 1.14%. The dividend is modest, but it complements the much larger repurchase program.
• Total Shareholder Yield: Dividend yield plus buyback yield is approximately 8.9%, meeting a demanding shareholder-return threshold and substantially exceeding the dividend yield alone.
• Reinvestment and M&A: SAIC uses selective acquisitions such as SilverEdge to strengthen strategic technology capabilities rather than pursuing indiscriminate scale. The main constraint is leverage, with net debt around $2.58B.
• Capital Allocation Quality: Management is currently directing cash toward both debt capacity and aggressive repurchases while generating strong FCF. At a single-digit P/FCF multiple, share retirement can create meaningful per-share value if operating performance remains stable.

Q2-A4. Step 2 Key Takeaways

• Scoring Rationale:
  • Economic Moat (7/10): Government incumbency, clearances and switching costs create a durable but non-monopolistic moat with only moderate pricing power.
  • Growth Sustainability (6/8): National-security digital modernization offers structural demand, but SAIC’s flat-to-negative organic guidance and 0.8x trailing book-to-bill prevent a full score.
  • Capital Allocation (7/7): Approximately 8.9% shareholder yield, aggressive share retirement and disciplined strategic M&A are highly shareholder-friendly.
• 📊 Step 2 Score: 20/25 pts (Economic Moat 7/10 + Growth Sustainability 6/8 + Capital Allocation 7/7)
• Step 2 Summary: SAIC combines meaningful government-contract barriers with exceptionally strong capital returns, but its moat has not yet translated into consistent organic top-line growth. Capital allocation is currently one of the strongest elements of the investment case.

💰 Step 3: Is Science Applications International Profitable? Financial Health Analysis

Q3-A1. Science Applications International’s Growth & Profitability Trends

• Revenue Has Been Mature Rather Than Structurally Expansive: FY2022 $7.39B ➔ FY2023 $7.70B ➔ FY2024 $7.44B ➔ FY2025 $7.48B ➔ FY2026 $7.26B ➔ TTM July 2026 $7.40B
• Operating Earnings Are Improving Despite Flat Revenue: FY2022 operating income $518M ➔ FY2023 $530M ➔ FY2024 $519M ➔ FY2025 $558M ➔ FY2026 $538M ➔ TTM July 2026 $609M
• Net Income and EPS Show Strong Per-Share Recovery: FY2022 net income $277M and EPS $4.77 ➔ FY2023 $300M and $5.38 ➔ FY2024 $477M and $8.88 ➔ FY2025 $362M and $7.17 ➔ FY2026 $358M and $7.70 ➔ TTM July 2026 $380M and $8.53. FY2024 included a material one-time divestiture gain, so underlying trend quality is better judged through operating profit and cash flow.
• Free Cash Flow Has Inflected Upward: FY2022 $482M ➔ FY2023 $507M ➔ FY2024 $369M ➔ FY2025 $458M ➔ FY2026 $577M ➔ TTM July 2026 $619M
• FCF Margin Expansion Is the Key Operating-Leverage Signal: FY2022 6.5% ➔ FY2023 6.6% ➔ FY2024 5.0% ➔ FY2025 6.1% ➔ FY2026 7.9% ➔ TTM July 2026 8.4%
• Operating Leverage Is Real but Margin-Led: Revenue remains close to its multi-year level while TTM operating income and FCF have moved materially higher, showing that contract profitability, cost control and share retirement are creating value even without strong top-line expansion.

Q3-A2. How Profitable Is Science Applications International? (Margins & ROIC)

• ROIC: Current ROIC is approximately 12.38%, versus a five-year average around 10.7%, indicating improving capital efficiency.
• ROIC-WACC Spread: Estimated WACC is approximately 5.29%, producing a current ROIC-WACC spread near +7.09 percentage points. SAIC is therefore generating economic returns comfortably above its cost of capital.
• ROE: Current ROE is approximately 25.74%, benefiting from profitability, financial leverage and a shrinking equity base from share repurchases.
• ROA: Current ROA is approximately 7.01%, a respectable level for a services integrator with substantial goodwill and acquired intangible assets.
• Competitive Profitability: SAIC’s approximately 10% adjusted EBITDA margin is solid for a government-services contractor, but the economics remain below high-margin proprietary software and therefore justify a moderate rather than exceptional valuation multiple.

Q3-A3. What Drives Science Applications International’s Returns? (ROIC Breakdown)

• Selected Efficiency Indicators: Backlog Coverage, Book-to-Bill and Asset Turnover — these indicators best capture SAIC’s ability to convert contracted government demand and its labor-intensive asset base into recurring revenue and returns.
  • Backlog Provides Multi-Year Revenue Coverage: Latest backlog is approximately $22.1B, almost 3.0x TTM revenue, creating meaningful forward visibility even though not every backlog dollar converts on a fixed schedule.
  • Book-to-Bill Is the Main Weakness: FY2026 book-to-bill was approximately 1.1x, but the latest trailing-twelve-month figure declined to 0.8x, implying that recent bookings have not fully replaced revenue consumed from backlog.
  • Asset Turnover Remains Efficient: Asset turnover is approximately 1.39x, consistent with a people-intensive service model that requires little physical capital and supports double-digit ROIC.
• Operational Driver: The key physical and operational lever is utilization of skilled, security-cleared labor across funded contract work, combined with maintaining recompete win rates and rapidly staffing newly awarded programs.
• Return Driver Conclusion: SAIC’s ROIC is driven less by fixed-asset efficiency than by contract incumbency, labor utilization, cash-light delivery and aggressive share retirement; sustained book-to-bill above 1.0x is the missing ingredient for stronger long-term compounding.

Q3-A4. Are Science Applications International’s Earnings High Quality?

• Cash Conversion: TTM OCF of approximately $660M materially exceeds TTM net income of roughly $380M, indicating strong conversion of accounting earnings into cash.
• OCF-to-Net-Income Trend: FY2024 83% ➔ FY2025 136% ➔ FY2026 170% ➔ TTM July 2026 174%
• Working-Capital Effect: Quarterly cash flow can fluctuate with contract billings, receivables and government payment timing, but multi-year OCF conversion is strong enough to demonstrate that reported profits are not dependent on non-cash accounting gains.
• Profit Quality Conclusion: Excluding the FY2024 divestiture-related gain, recurring cash generation has strengthened materially, making cash-flow quality one of SAIC’s best fundamental attributes.

Q3-A5. Is Science Applications International’s Balance Sheet Healthy? (Debt & Leverage)

• Debt Load: Total debt is approximately $2.71B, cash is approximately $126M, and net debt is about $2.58B.
• Leverage: Net debt-to-EBITDA is approximately 3.43x, an elevated but manageable level for a company with durable federal contract revenue and strong free cash flow.
• Liquidity: The current ratio is about 1.20x and quick ratio approximately 1.06x, indicating sufficient near-term liquidity but not an unusually large liquidity cushion.
• Interest Coverage: EBIT-to-interest expense is approximately 4.48x, providing adequate interest-service capacity while leaving leverage as a factor that management must actively manage.
• Refinancing Risk: Strong annual FCF exceeding $600M on a TTM basis gives SAIC substantial internal debt-reduction capacity, reducing near-term solvency risk despite its leveraged capital structure.

Q3-A6. Step 3 Key Takeaways

• Scoring Rationale:
  • Profitability·Capital Efficiency (8/10): ROIC comfortably exceeds WACC and margins are improving, but stagnant multi-year revenue prevents an elite profitability score.
  • Cash Flow·Profit Quality (8/8): OCF consistently exceeds normalized net income and FCF has climbed to more than $600M TTM.
  • Financial Soundness·Debt Management (5/7): Cash generation is strong, but approximately 3.4x net debt-to-EBITDA and modest liquidity warrant a deduction.
• 📊 Step 3 Score: 21/25 pts (Profitability·Capital Efficiency 8/10 + Cash Flow·Profit Quality 8/8 + Financial Soundness·Debt Management 5/7)
• Step 3 Summary: SAIC is highly cash generative and economically profitable, with improving capital efficiency and real margin leverage. The major financial constraint is leverage rather than earnings quality.

🔎 Step 4: Science Applications International Forensic Accounting & Dilution Review

Q4-A1. Does Science Applications International Have Accounting Red Flags?

• Revenue recognition: not found
  • Evidence: SAIC recognizes substantial long-term contract revenue under established government-contract accounting and ASC 606 principles. Recent disclosure does not indicate an unusual acceleration in revenue recognition, while prior-period contract-estimate adjustments have been small relative to total revenue.
• Cost capitalization: not found
  • Evidence: TTM capital expenditure is only approximately $41M against $7.4B of revenue, and there is no indication that operating costs are being systematically shifted onto the balance sheet to inflate earnings.
• Sharp increase in accounts receivable and inventory: not found
  • Evidence: Receivables around $1.0B are consistent with the scale of government contract revenue and have not grown disproportionately to sales. Inventory is not a material balance-sheet driver for SAIC’s services model.
• Non-recurring adjustment (normalization): discovered
  • Evidence: FY2024 net income was boosted by an approximately $247M gain associated with a business disposition. Normalized profitability should therefore rely more heavily on operating income, adjusted EBITDA and recurring cash flow than that year’s GAAP net income.

Q4-A2. Is Science Applications International Overspending? (Capex & Capital Cycle)

• ➖ Not applicable: SAIC is a labor- and contract-intensive technology integrator rather than a manufacturing capacity business. TTM capital expenditure of only approximately $41M means industry capacity oversupply and heavy physical-capital cycles are not the relevant economic risk.

Q4-A3. How Sound Is Science Applications International’s Cash Flow?

• Operating Cash Generation: TTM OCF is approximately $660M, comfortably above TTM net income of approximately $380M, providing no evidence of a persistent NI-greater-than-OCF warning signal.
• Free Cash Flow: TTM FCF is approximately $619M, while FY2026 FCF was $577M and management continues to guide to more than $600M for FY2027.
• Financing Dependence: SAIC does carry substantial debt, but core operations generate enough cash to fund dividends, repurchases, selective acquisitions and potential debt reduction without requiring recurring equity issuance.
• Warning Signal Classification: No persistent multi-quarter cash-flow deterioration is present. Cash conversion has strengthened rather than weakened.

Q4-A4. Is Science Applications International Diluting Shareholders?

• Confirmed Past Dilution: Share count has moved decisively in the opposite direction of dilution, with shares outstanding declining approximately 7.76% YoY to 41.90M as aggressive repurchases more than offset stock-based compensation.
• Potential Future Dilution & Overhang: TTM SBC is approximately $67M, material but substantially smaller than roughly $479M of TTM share repurchases. No major convertible, warrant, ATM or lock-up overhang appears capable of reversing the current net share-count contraction.
• Per-Share Effect: Because buybacks materially exceed SBC issuance, SAIC’s capital structure currently creates meaningful EPS and FCF-per-share accretion rather than shareholder dilution.

Q4-A5. Data Integrity Check

• Period: TTM through July 31, 2026 is used for current operating and valuation figures, while fiscal-year values are explicitly identified by fiscal period ➡ (Pass)
• Definition: GAAP net income is separated from adjusted EBITDA, adjusted EPS and company-defined FCF, with one-time FY2024 divestiture gains normalized where relevant ➡ (Pass)
• Number of Shares: Current end-of-period shares outstanding of 41.90M are separated from weighted-average diluted shares used for reported EPS ➡ (Pass)
• Unit: Financial figures are standardized in USD millions or billions and valuation multiples are presented as ratios without currency symbols ➡ (Pass)
• Single Value Confirmation: SEC and company disclosures reconcile sufficiently with current financial-platform values after aligning periods and definitions ➡ (Pass)

Q4-A6. Step 4 Key Takeaways

• Scoring Rationale:
  • Accounting anomalies·distortion signals (7/8): No material accounting red flags were identified, although the FY2024 one-time divestiture gain requires normalization.
  • Cash flow warning signals (7/7): Cash conversion is strong, with TTM OCF and FCF both comfortably positive and improving.
  • Dilution factors (5/5): Repurchases substantially exceed SBC and the share count has contracted nearly 8% YoY.
• 📊 Step 4 Score: 19/20 pts (Accounting anomalies·distortion signals 7/8 + Cash flow warning signals 7/7 + Dilution factors 5/5)
• Step 4 Summary: SAIC’s forensic profile is clean, cash earnings are strong and aggressive repurchases create substantial anti-dilution. The principal normalization issue is a historical one-time divestiture gain rather than a recurring accounting concern.

👔 Step 5: Science Applications International Management & Shareholder Alignment

Q5-A1. Can You Trust Science Applications International’s Management? (Guidance Track Record)

• Guidance Execution: FY2026 adjusted EPS finished at approximately $10.75 and FCF at $577M, with cash generation exceeding prior expectations even as revenue remained pressured. In Q2 FY2027, management raised revenue, adjusted EBITDA, margin and adjusted EPS guidance after stronger quarterly execution.
• FY2027 Guidance: Revenue is now guided to $7.2B-$7.3B, organic growth to -2% to 0%, adjusted EBITDA to $750M-$755M, adjusted EBITDA margin to 10.3%-10.5%, adjusted EPS to $10.65-$10.75, and FCF to more than $600M.
• Credibility: Management is not masking the top-line problem: organic guidance remains explicitly weak despite strong Q2 growth. That transparency is constructive, although sustained contract wins will be needed before the market can regard guidance execution as consistently high-confidence.
• Leadership Reset: James Reagan became interim CEO in October 2025 and permanent CEO in February 2026, so his record as SAIC’s chief executive is still short. Early evidence shows stronger margin execution and clearer operational discipline.

Q5-A2. What Are Science Applications International Insiders Doing?

• James Reagan Transaction: On February 17, 2026, CEO James Reagan disposed of 8,861 shares at approximately $86.61 under Form 4 transaction code F, representing shares withheld to satisfy tax obligations rather than a discretionary open-market bearish sale.
• Director Equity Awards: Recent Form 4 activity includes compensation-related equity grants to directors, including awards made in June 2026, rather than broad open-market buying.
• Net Discretionary Flow: Reviewed SEC insider filings do not show a meaningful cluster of voluntary open-market insider purchases during the trailing year, nor do they show a verified pattern of senior executives abandoning the stock through discretionary open-market sales. The observable flow is dominated by compensation grants and tax-withholding transactions.
• Confidence Signal: Insider behavior is therefore neutral rather than strongly bullish: there is no open-market buying signal, but the most visible CEO disposition was mechanical and should not be interpreted as a fundamental exit.

Q5-A3. Is Science Applications International’s Management Aligned With Shareholders?

• Voting Rights and Governance: SAIC uses a conventional public-company governance structure rather than a founder-controlled dual-class system, giving ordinary shareholders conventional voting rights.
• Performance Compensation: Executive short-term incentives are linked to revenue, adjusted EBITDA and adjusted operating cash flow, connecting management pay to growth, profitability and cash generation.
• Long-Term Incentives: Performance-share awards represent a substantial portion of long-term compensation and use cumulative adjusted EBITDA, cumulative adjusted FCF and relative TSR over multi-year periods, aligning management with both operating and market outcomes.
• Pay-for-Performance Evidence: FY2026 incentive outcomes reflected weaker revenue and EBITDA performance rather than paying executives as though targets had been fully achieved, supporting the credibility of the framework.
• Alignment Limitation: Insider ownership remains relatively low at approximately 1.08%, so alignment comes more from compensation design and share repurchases than from unusually large personal ownership stakes.

Q5-A4. Step 5 Key Takeaways

• Scoring Rationale:
  • Management Trust (4/5): Guidance communication is transparent and recent execution is improving, although Reagan’s CEO track record remains short.
  • Insider Trends (2/5): No damaging discretionary selling pattern is evident, but the absence of meaningful open-market insider buying provides little positive signal.
  • Governance·Compensation System (4/5): Compensation emphasizes EBITDA, FCF and relative TSR, creating solid shareholder alignment despite low insider ownership.
• 📊 Step 5 Score: 10/15 pts (Management Trust 4/5 + Insider Trends 2/5 + Governance·Compensation System 4/5)
• Step 5 Summary: Management incentives are sensibly structured around profitability, cash flow and shareholder returns, while the new CEO’s early execution is encouraging. The main weakness is the lack of a strong insider-ownership or open-market-buying signal.

⛵ Step 6: Science Applications International Market Flow & Sentiment

Q6-A1. Analyst Consensus vs Science Applications International Guidance

• Revenue Expectations: Company FY2027 revenue guidance of $7.2B-$7.3B has a midpoint of approximately $7.25B, while the latest analyst consensus is approximately $7.29B, leaving consensus only modestly above management’s midpoint.
• EPS Expectations: FY2027 adjusted EPS guidance of $10.65-$10.75 has a midpoint of $10.70, versus consensus near $10.81, again implying that analysts expect a modest beat but not an extreme one.
• Recent Revision Direction: Analyst targets moved upward after Q2 FY2027 results, including several September increases, while the aggregate rating remains Hold. The market is recognizing better margins and execution without fully embracing a durable growth acceleration.
• Priced Expectations: Consensus is not dramatically detached from management guidance, reducing classic priced-for-perfection risk. The more important question is whether future bookings support FY2028 growth after a flat FY2027 organic base.

Q6-A2. What Is Science Applications International’s Short Interest?

• Institutional Ownership: Institutions own approximately 87.51% of shares, reflecting deep professional-investor participation and leaving relatively limited retail influence on the float.
• Short Interest: As of August 31, 2026, approximately 2.41M shares were sold short, equal to about 5.79% of public float.
• Days-to-Cover: The short-interest ratio was approximately 4.37 days, a meaningful but not extreme level.
• Trend: Short interest declined approximately 11.2% from the previous reporting period, suggesting bearish positioning eased following improving operating results.
• Market Flow Conclusion: SAIC has enough short interest to amplify a positive earnings or award surprise, but the setup is not severe enough to make a short squeeze a core investment thesis.

Q6-A3. Step 6 Key Takeaways

• Scoring Rationale:
  • Consensus vs Guidance (2/3): Consensus is only modestly above management’s raised outlook, leaving manageable expectations.
  • Supply·Short Interest (2/2): Short interest is moderate and falling, while institutional ownership is high and liquidity remains healthy.
• 📊 Step 6 Score: 4/5 pts (Consensus vs Guidance 2/3 + Supply·Short Interest 2/2)
• Step 6 Summary: Market expectations have improved but remain disciplined, while short positioning has begun to recede. SAIC is no longer priced as a deeply disliked stock, but sentiment is still far from euphoric.

🚀 Step 7: Science Applications International Catalysts & Price Triggers

Q7-A1. What Could Move Science Applications International Stock? (Top 3 Catalysts)

• 1 Book-to-Bill Recovery Above 1.0x
  • Timing: Next 6-12 months, beginning with the next two quarterly bookings updates.
  • Success Conditions: Large intelligence, space and defense wins lift trailing book-to-bill from 0.8x to sustainably above 1.0x and backlog resumes growth, giving investors evidence that current revenue pressure is ending.
  • Failure Risk: Bookings remain below revenue consumption, backlog continues shrinking and FY2028 growth expectations are revised downward.
• 2 Organic Growth Reacceleration After the Q2 FY2027 Rebound
  • Timing: Q3-Q4 FY2027 results and initial FY2028 guidance.
  • Success Conditions: The 5.3% Q2 organic growth result proves to be more than timing noise, contract ramps offset completions and management exits the current -2% to 0% FY2027 organic-growth framework with a positive FY2028 outlook.
  • Failure Risk: Q2 strength reverses, contract starts slip and organic growth returns to negative territory.
• 3 Margin and Free-Cash-Flow Execution Above Raised Guidance
  • Timing: Remaining FY2027 earnings releases and FY2028 outlook.
  • Success Conditions: Adjusted EBITDA margin holds at or above the 10.3%-10.5% guidance range while annual FCF exceeds $600M, enabling continued aggressive repurchases without materially worsening leverage.
  • Failure Risk: Contract mix, labor costs or execution problems push margins lower and force management to slow buybacks to protect the balance sheet.

Q7-A2. Science Applications International’s Earnings Revision Trend

• EPS Revision Direction: FY2027 adjusted EPS consensus is approximately $10.81, slightly above the company’s $10.65-$10.75 guidance range, and analyst price targets were broadly revised upward after the August 31 earnings release.
• FY2028 Expectations: Consensus FY2028 EPS is approximately $11.39, implying about 5.3% year-over-year growth, while consensus revenue of approximately $7.38B implies only about 1.3% growth.
• Revision Quality: Recent revisions reflect better profitability and cash generation more than a dramatic top-line growth thesis. That distinction matters because a durable valuation rerating will require bookings and organic revenue, not merely additional cost savings.

Q7-A3. Step 7 Key Takeaways

• Scoring Rationale:
  • Catalyst (6/7): Bookings recovery, organic growth normalization and sustained margin execution are identifiable and measurable catalysts, though none is guaranteed.
  • EPS Trend (3/3): Recent earnings expectations and multiple analyst targets have moved upward following stronger Q2 execution.
• 📊 Step 7 Score: 9/10 pts (Catalyst 6/7 + EPS Trend 3/3)
• Step 7 Summary: SAIC has several credible rerating triggers, led by a recovery in bookings and proof that Q2’s organic rebound can persist. Earnings momentum is positive, but revenue momentum remains the decisive confirmation signal.

⚖️ Step 8: Is Science Applications International Fairly Valued? Valuation Analysis

Q8-A1. Science Applications International’s Key Valuation Multiples

• PE Ratio: 15.04x (fairly valued)
• PS Ratio: 0.71x (very undervalued)
• PB Ratio: 3.69x (fairly valued)
• P/TBV Ratio: N/A (unverifiable)
• P/FCF Ratio: 8.54x (very undervalued)
• P/OCF Ratio: 8.01x (very undervalued)
• EV/Sales Ratio: 1.06x (undervalued)
• EV/EBITDA Ratio: 10.45x (fairly valued)
• EV/EBIT Ratio: 13.20x (fairly valued)
• EV/FCF Ratio: 12.71x (undervalued)
• Forward PE: 12.51x (undervalued)
• PEG Ratio: N/A (unverifiable)
• Scoring Rationale: Cash-flow and sales multiples are distinctly inexpensive in absolute terms, while earnings and enterprise-value multiples are closer to normal mature-contractor levels. The overall basket therefore screens undervalued but not distressed.
• 📌 (1) Axis Q8-A1 Score: +3

Q8-A2. Science Applications International vs Peers: Valuation Comparison

• Multiple selection based on peer comparison: Forward P/E is selected because SAIC and all comparison peers are profitable and have forward earnings estimates. SAIC trades at 12.51x, versus Leidos 10.67x, Booz Allen Hamilton 11.90x, CACI 18.55x and KBR 9.15x, for a peer mean of approximately 12.57x.
• Calculation of peer-to-peer deviation rate: -0.46%
  • 🧮 Calculation Formula: ((12.51x - 12.57x) ÷ 12.57x) × 100 = -0.46%
• Scoring Rationale: SAIC’s forward P/E is essentially identical to the selected peer mean, providing neither a meaningful premium nor discount signal.
• 📌 (2) Axis Q8-A2 Score: 0

Q8-A3. Is Science Applications International Cheap or Expensive vs Its History?

• Comparison Indicators: Trailing P/E is used as the first valid priority metric. SAIC’s current 15.04x compares with a recent five-year annual observed range of approximately 12.83x-18.95x, placing the current multiple around 36% of the way from the trough to the peak.
• Scoring Rationale: A position around the lower 20-40% portion of the observed range qualifies as historically undervalued. The stock is above its absolute trough but meaningfully below its historical upper band.
• 📌 (3) Axis Q8-A3 Score: +2

Q8-A4. What Growth Is Priced Into Science Applications International? (Reverse DCF)

• Implied Growth Rate: 9.8%
  • 1 Methodology: A simplified earnings-multiple inversion solves for the five-year EPS CAGR required for today’s price to earn an 8.0% annual return at a 14.0x terminal P/E.
  • 2 Core assumptions: Current price $129.90, TTM EPS $8.53, five-year horizon, 14.0x terminal P/E and 8.0% required annual return, with dividends excluded for conservatism.
• Achievable Growth Rate: 5.3%
  • Basis: Latest FY2028 adjusted EPS consensus of approximately $11.39 implies about 5.3% growth from FY2027 consensus, a more realistic near-term earnings trajectory than the materially higher growth embedded in the simplified inversion.
• Growth gap and difficulty assessment:
  • 🧮 Formula: Achievable Growth Rate 5.3% - Implied Growth Rate 9.8% = -4.5%p
• Scoring Rationale: The implied earnings-growth hurdle materially exceeds near-term consensus growth, so the current price requires sustained operating improvement beyond the present revenue trajectory. That creates a moderate growth-justification valuation burden despite otherwise inexpensive multiples.
• 📌 (4) Axis Q8-A4 Score: -3

Q8-A4-1. What Growth Hurdle Does the Market Demand From Science Applications International? (Reverse DCF Alternative)

• Scoring Rationale: (Not applicable)
• 📌 (4) Axis Q8-A4-1 Score: ➖

Q8-A5. Valuation Cross-Check

• Scoring Rationale:
  • (1) Axis Q8-A1 (Key Valuation Indicator): Undervalued
  • (2) Axis Q8-A2 (Peer-to-peer deviation rate): Fairly Valued
  • (3) Axis Q8-A3 (Historical Band Position): Undervalued
  • (4) Axis Q8-A4 (Justification for Growth): Overvalued
  • Reasons for Directional Mismatch: Only two of the four axes point in the same direction. Cheap cash-flow multiples and a lower historical-band position conflict with neutral peer valuation and a demanding reverse-growth hurdle, so no three-axis consensus exists.
• 📌 (5) Axis Q8-A5 Score: -2

Q8-A6. Science Applications International’s Hidden Asset & Stake Valuation

• Scoring Rationale: (Not applicable)
• 📌 (6) Axis Q8-A6 Score: ➖

Q8-A7. Final Valuation Adjustment

• Scoring Rationale: No separate valuation factor is sufficiently distinct from the six preceding axes to justify another adjustment. Share repurchases, leverage and operating improvements are already reflected in per-share fundamentals and current multiples.
• 📌 (7) Axis Q8-A7 Score: 0

Q8-A8. Valuation Adjustment Score Calculation

• Calculation Process:
  • (1) Axis (Key Valuation Indicators): +3 pts (Undervalued)
  • (2) Axis (Peer-to-peer deviation rate): 0 pts (-0.46% vs peers)
  • (3) Axis (Historical Band Position): +2 pts (Bottom 20-40%)
  • (4) Axis (Justification for Growth): -3 pts (Achievable growth trails implied growth by 4.5 percentage points)
  • (5) Axis (Cross-Verification Adjustment): -2 pts (mismatch between valuation models)
  • (6) Axis (Held assets·Share Valuation): 0 pts (Not applicable)
  • (7) Axis (Final adjustment): 0 pts (No additional adjustment)
• 📊 Valuation Adjustment Score: A1 (+3) + A2 (0) + A3 (+2) + A4 (-3) + A5 (-2) + A6 (0) + A7 (0) = 0 pts
• Commentary: SAIC looks inexpensive on cash flow and its own historical range, but it is not meaningfully cheaper than direct peers and today’s price still assumes earnings growth faster than near-term consensus. The opposing signals cancel mechanically rather than producing a strong valuation advantage.
• Step 8 Summary: Valuation is attractive enough to limit downside from multiple compression, but not cheap enough relative to peers and growth expectations to create a standalone rerating thesis.

💀 Step 9: What Are the Risks of Science Applications International? Fatal Risks & Pre-Mortem

Q9-A1. What Are the Biggest Risks to Science Applications International?

• 1 Weak Bookings and Backlog Conversion Could Keep Organic Growth Stagnant:
  • Cause: Trailing-twelve-month book-to-bill has fallen to 0.8x, meaning recent bookings have not fully replaced revenue being consumed.
  • Impact: Persistent sub-1.0x bookings could force backlog and revenue estimates lower and eventually weaken the current margin-led EPS story.
  • Mitigation: A $22.1B backlog, major recompete wins and growing intelligence and space opportunities provide time for management to rebuild award momentum.
• 2 Extreme Dependence on U.S. Federal Procurement Creates Policy and Timing Risk:
  • Cause: Virtually all revenue comes from U.S. government customers, exposing SAIC to appropriations delays, continuing resolutions, shutdowns, recompetes and shifting agency priorities.
  • Impact: Even without losing strategic relevance, contract start dates can slip and customer funding can move between periods, producing abrupt organic-growth volatility.
  • Mitigation: SAIC is diversified across defense, intelligence, space and civilian agencies and works on mission-critical programs that generally retain long-term funding priority.
• 3 Leverage and Integration Execution Could Constrain Capital Allocation:
  • Cause: Net debt is approximately $2.58B and net debt-to-EBITDA roughly 3.43x, while SAIC is simultaneously funding acquisitions and aggressive buybacks.
  • Impact: A cash-flow miss or acquisition underperformance could require reduced repurchases, slowing one of the most powerful current EPS-per-share drivers.
  • Mitigation: More than $600M of annualized FCF capacity provides substantial internal deleveraging capability if management prioritizes the balance sheet.

Q9-A2. How Sensitive Is Science Applications International to the Economy?

• 1 U.S. Federal Budget and Appropriations Cycle (⬇): A prolonged continuing resolution, shutdown or slower appropriations process can delay contract awards and task-order funding, depressing near-term revenue even when long-term mission demand remains intact.
• 2 Defense and Intelligence Modernization Spending (⬆): Stronger funding for cyber, space, command-and-control, AI and digital engineering expands SAIC’s opportunity pipeline and can lift bookings, backlog and organic growth.
• 3 Labor Cost and Security-Cleared Talent Availability (⬇): Tight supply of specialized cleared personnel raises compensation costs and can delay staffing of new programs, pressuring margins and revenue conversion if contract pricing does not fully compensate for wage inflation.

Q9-A3. Science Applications International Pre-Mortem: What Could Go Wrong?

• 1 The backlog quietly deteriorates despite impressive headline contract awards: Book-to-bill stays below 1.0x for several more quarters, existing contracts roll off faster than new wins ramp and investors discover that the apparent $22.1B backlog was insufficient to restart sustainable growth.
• 2 The margin story proves temporary: Management sustains EPS through cost control and buybacks while organic revenue remains negative, then wage inflation or unfavorable contract mix pushes EBITDA margin back below 10%, simultaneously weakening earnings and valuation support.
• 3 Capital allocation becomes overextended: Buybacks and acquisitions remain aggressive while leverage stays above 3x, a government-funding disruption hits cash flow and management is forced to reduce repurchases precisely when operating momentum weakens.

Q9-A4. Risk Adjustment Score

• Reason for Scoring: The central growth risk is already visible in measurable operating indicators: FY2027 organic revenue guidance is -2% to 0% and trailing book-to-bill is 0.8x. These are quantified signs of top-line pressure rather than purely hypothetical concerns, although strong backlog, margins and cash flow keep the risk far from structural distress.
• 📊 Risk Adjustment Score: -11 pts
• Step 9 Summary: SAIC’s risks are operational and procurement-related rather than existential. The measurable deterioration in bookings and flat organic-growth outlook deserves a material deduction, but strong cash generation and mission-critical exposure provide meaningful resilience.

🎯 Step 10: Science Applications International Final Verdict: Score & Rating

Q10-A1. Investment Score & Rating

• Investment Score Calculation Formula:
  • Step breakdown: S2 (20) + S3 (21) + S4 (19) + S5 (10) + S6 (4) + S7 (9) = 83 pts
  • Steps 2-7 Sum (83 pts) + Valuation Adjustment (0 pts) + Risk Adjustment (-11 pts) = Investment Score 72 pts
• Investment Score & Rating: 72 pts (B Rating ⭐⭐⭐)
  • Commentary: SAIC’s exceptional cash conversion, anti-dilutionary repurchases, improving margins and durable government franchise create a strong fundamental base. That strength is offset by measurable bookings weakness, flat organic-growth guidance and a valuation that is cheap on cash flow but less compelling once peer comparisons and implied growth requirements are considered.

Q10-A2. Should You Buy Science Applications International? (Recommendation)

• Recommendation: Hold
  • Commentary: Existing shareholders have good reasons to remain invested because cash generation, repurchases and mission-critical demand provide substantial support, but new buyers should seek a better entry point or evidence that book-to-bill and organic growth are sustainably turning upward.

Q10-A3. Investment Thesis in One Line

• Science Applications International is a cash-rich government technology integrator compounding per-share value through improving margins and aggressive buybacks, but sub-1.0x book-to-bill and weak organic-growth guidance still prevent the stock from becoming a high-conviction growth-and-value opportunity.

Q10-A4. Science Applications International’s Price Trend & Key Drivers

• Stock Price Trends Over the Past 12 Months: upward 📈
• October 23, 2025 Unexpected Chief Executive Officer transition
  • Description: The sudden appointment of James Reagan as interim CEO added execution uncertainty to an already weak growth narrative, keeping the stock under pressure while investors waited for a credible operational reset. ➡ Stock Price Pressure
• March 16, 2026 FY2026 results highlighted strong cash flow despite top-line weakness
  • Description: FY2026 FCF reached $577M and management established a margin-improvement plan under permanent CEO Reagan, helping shift attention from shrinking revenue toward cash generation, operating discipline and capital returns. ➡ Stock Price Recovery
• August 31, 2026 Q2 FY2027 earnings delivered 5.3% organic growth and raised guidance
  • Description: Revenue grew 6.3%, organic growth reached 5.3%, adjusted EBITDA margin reached 10.3% and management increased several full-year guidance ranges, strengthening confidence that execution was improving. ➡ Stock Price Re-Rating

Q10-A5. Action Plan

• Current Price: $129.90
• Buy Zone: $120.00 ($116.00–$124.00)
  • (1) Calculation of Fundamental Value: A buy range in the upper-$110s to low-$120s places the stock closer to its lower historical valuation band and provides a more attractive margin of safety against flat organic-growth guidance.
  • (2) Momentum Premium/Discount Application: SAIC receives no material momentum premium because the business has not yet demonstrated sustained book-to-bill above 1.0x, although improving earnings momentum justifies avoiding an unrealistically deep-value entry requirement.
  • (3) Conclusion: $116.00-$124.00 is the preferred accumulation range, with a $120.00 midpoint balancing historical valuation support against the improving Q2 operating trend.
• Price Target: $143.16
• Expected Return: +10.2% (vs. current price)
  • 📍 Select target stock price calculation criteria:
    • Forward P/E — profitable government-services peers provide a clean same-source valuation anchor, while FY2028 consensus EPS captures the next 12-month earnings power better than trailing GAAP EPS.
  • 🧮 Price Target Calculation Formula:
    • Per share indicator based (Forward PER, P/FCF, etc.): $11.39 × 12.57x = $143.16
    • Basis for applying the multiple: Q8-A2 peer-average Forward P/E anchor of 12.57x — 12.57x — no premium or discount is applied because SAIC’s current forward multiple is already almost exactly aligned with peers.
• Conditions and timing for reaching price target: The target becomes most credible if the next two earnings releases show book-to-bill recovering toward or above 1.0x while adjusted EBITDA margin remains at least within the 10.3%-10.5% FY2027 guidance range; a positive FY2028 organic-growth outlook would provide the strongest confirmation.
• Stop Loss: $106.00 ($103.00–$109.00)
• Action trigger upon catalyst achievement:
  • 1 Book-to-bill sustainably recovers above 1.0x
    • Description: This would confirm that new awards are replenishing revenue consumption and materially improve forward organic-growth visibility. 👉 Increase Holdings (Buy)
  • 2 Organic growth remains positive through the next two quarterly reports
    • Description: Sustained positive organic growth would demonstrate that the Q2 rebound was structural rather than timing-related and would justify a higher earnings and valuation framework. 👉 Increase Holdings (Buy)
  • 3 Adjusted EBITDA margin and FCF exceed raised FY2027 guidance
    • Description: Strong margin and cash execution would expand the resources available for debt reduction and accretive repurchases even before faster revenue growth arrives. 👉 Continue Holding / Selective Buy
• Action trigger upon risk realization:
  • 1 Trailing book-to-bill remains below 0.8x and backlog falls materially
    • Description: Persistent under-replacement of consumed backlog would weaken the forward revenue base and invalidate the expected growth recovery. 👉 Reduce Holdings (Sell)
  • 2 FY2028 guidance signals another year of negative organic growth
    • Description: A second year of contraction would indicate a structural competitive or portfolio problem rather than a temporary procurement cycle. 👉 Reduce Holdings (Sell)
  • 3 FCF drops below $500M while leverage remains above 3x
    • Description: A simultaneous cash-flow and leverage deterioration would threaten the buyback engine and materially weaken per-share compounding. 👉 Reduce Holdings (Sell)
• Customized Strategy Guide by Investment Preference:
  • Defensive Investors: Wait for the $116.00-$124.00 buy zone or for book-to-bill to recover above 1.0x before initiating a meaningful position; prioritize downside protection over chasing the current rerating.
  • Neutral Investors: Maintain an existing moderate position, add selectively near the $120.00 midpoint and increase exposure only if bookings and FY2028 growth visibility improve.
  • Aggressive Investors: A small position can be held near current levels to capture further execution upside, but reserve substantial capital for either a pullback into the buy zone or definitive evidence of a bookings inflection.

🕵️‍♂️ Deep Dive Analysis

Q1: Is Science Applications International’s 0.8x Book-to-Bill Ratio Its Biggest Weakness?

• Analysis: Yes, because the company’s current investment debate is no longer about profitability or cash conversion; both are strong. A trailing book-to-bill ratio below 1.0x means SAIC is consuming backlog faster than it is replacing it, which is consistent with management’s -2% to 0% FY2027 organic-growth guidance. The $22.1B backlog provides a large buffer, but sustained sub-1.0x bookings would eventually translate into weaker revenue even if margins continue improving.
• Judgment: Negative — book-to-bill is the clearest quantitative signal preventing SAIC from being treated as a durable growth compounder today.

Q2: Can Science Applications International’s 12.51x Forward P/E Be Justified by Its Flat Organic Growth?

• Analysis: The multiple is defensible because SAIC converts a high proportion of earnings to cash, retires shares aggressively and trades almost exactly at the selected peer average of 12.57x. However, a simplified growth inversion suggests the current price still requires earnings growth faster than near-term consensus. The valuation is therefore inexpensive in absolute cash-flow terms but not obviously mispriced relative to other government integrators.
• Judgment: Fairly Valued — 12.51x is not demanding, but flat organic growth prevents the multiple itself from creating a compelling asymmetric opportunity.

Q3: Can Science Applications International’s $22.1B Backlog Restart Sustainable Organic Growth?

• Analysis: Backlog represents roughly three times annual revenue, giving SAIC excellent nominal visibility. The problem is composition and replenishment: funded backlog is only a fraction of total backlog, awards convert on different schedules, and trailing book-to-bill of 0.8x shows that headline backlog size alone does not guarantee growth. The strongest signal would be simultaneous improvement in funded backlog and book-to-bill above 1.0x.
• Judgment: Neutral — backlog provides downside protection, but its current trajectory does not yet prove a durable growth restart.

Q4: Can Science Applications International Sustain a 10.3%-10.5% Adjusted EBITDA Margin?

• Analysis: Recent evidence is favorable. Q2 FY2027 adjusted EBITDA margin reached 10.3%, while management raised its full-year range to 10.3%-10.5%. The company’s asset-light delivery model, portfolio discipline and operational reset provide room for productivity gains, but contract mix and wage inflation can quickly erode service-industry margins. Maintaining this range while organic revenue normalizes would materially improve earnings quality.
• Judgment: Positive — margin expansion appears operationally supported rather than purely cyclical, though continued contract-mix discipline is essential.

Q5: Is Science Applications International’s $619M TTM Free Cash Flow Its Strongest Competitive Financial Advantage?

• Analysis: FCF is arguably SAIC’s strongest investment attribute because it gives management several simultaneous options: retire shares, reduce debt, fund dividends and buy strategic capabilities. TTM FCF around $619M equals more than 11% of the company’s current market capitalization, an unusually high cash yield for a stable government-contractor franchise. This cash generation is also less dependent on strong revenue growth than a conventional growth-stock thesis.
• Judgment: Positive — the free-cash-flow engine substantially improves downside resilience and per-share compounding potential.

Q6: Does James Reagan’s Leadership Reset Improve Science Applications International’s Execution Odds?

• Analysis: Reagan’s government-services operating background and early emphasis on reliable growth, margin discipline and value creation fit SAIC’s current problem set. Since his appointment, the company has demonstrated better margin execution and raised FY2027 guidance after Q2. The limitation is time: he has been permanent CEO only since February 2026, so the market has not yet seen a full bookings and revenue cycle under his leadership.
• Judgment: Positive but unproven — early operational evidence is encouraging, but sustainable contract growth is required before declaring the leadership reset successful.

Q7: Can Science Applications International Keep Retiring Nearly 8% of Its Share Count Annually?

• Analysis: TTM FCF exceeding $600M and a relatively low valuation make repurchases highly accretive, and the current 7.76% YoY share-count reduction materially lifts per-share economics. Replicating that pace indefinitely is unlikely because SAIC also carries approximately $2.6B of net debt and may need capital for strategic acquisitions. Even a lower repurchase rate, however, could still create substantial per-share growth if FCF remains stable.
• Judgment: Positive — the current pace may normalize, but buybacks should remain an important compounding lever.

Q8: Does Science Applications International’s 3.43x Net Debt-to-EBITDA Limit Capital Allocation?

• Analysis: Leverage is the principal balance-sheet constraint. It is high enough that a material cash-flow miss would force difficult tradeoffs between acquisitions, debt reduction and repurchases, but not high enough to constitute a solvency problem given strong federal-contract revenue and cash conversion. The best outcome is gradual deleveraging through EBITDA and FCF growth rather than sacrificing all buybacks.
• Judgment: Neutral — leverage limits optionality but remains manageable under the current cash-generation profile.

Q9: Can SilverEdge Turn Science Applications International Into a Higher-Value Mission Technology Integrator?

• Analysis: SilverEdge adds cyber, software, AI and data capabilities concentrated in intelligence and defense, precisely where SAIC wants to increase differentiated mission work. The strategic logic is stronger than buying undifferentiated scale, but the acquisition is too small relative to SAIC’s $7B-plus revenue base to transform consolidated growth by itself. Its value will come from cross-selling and improving win rates on larger programs.
• Judgment: Positive but incremental — SilverEdge can improve portfolio quality and competitive differentiation, but it is not independently large enough to change SAIC’s growth profile.

Q10: What Would Make Science Applications International Break Out Above Its Historical Valuation Range?

• Analysis: A lasting rerating requires a combination rather than a single quarter: trailing book-to-bill above 1.0x, sustained positive organic growth, adjusted EBITDA margin above 10%, FCF above $600M and continued net share retirement. If those conditions coexist, investors could stop valuing SAIC as a mature ex-growth contractor and begin paying a premium for dependable per-share compounding.
• Judgment: Conditional Positive — the operational ingredients exist, but bookings growth is the missing proof needed for a structural multiple expansion.